Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023

A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individu...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Euro surveillance : bulletin européen sur les maladies transmissibles Ročník 28; číslo 49; s. 1
Hlavní autoři:	Martinón-Torres, Federico, Mirás-Carballal, Susana, Durán-Parrondo, Carmen
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Sweden Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) 07.12.2023 European Centre for Disease Prevention and Control (ECDC)
Témata:	Antibodies, Monoclonal - therapeutic use Antiviral Agents - therapeutic use Babies Clinical outcomes Disease prevention Humans Immunization Infant Monoclonal antibodies Palivizumab - therapeutic use Rapid Communication Respiratory syncytial virus Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus, Human Respiratory Syncytial Viruses Spain Spain Galicia Spain Respiratory Syncytial Virus immunoprophylaxis nirsevimab implementation long-acting monoclonal antibodies
ISSN:	1560-7917, 1025-496X, 1560-7917
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!